Pablo Legorreta
Showing 1–5 of 5 transcripts.
- Milken Institute1h 3m
In Service of a Healthier Tomorrow | Global Conference 2025
Esther Krofah, Gregory Case, Judy Faulkner, Robert Ford, Pablo Legorreta, Ellen Sigal, Greg Case
Leading industry figures including Epic's Judy Faulkner and Aon's Greg Case outline a strategic roadmap for the US healthcare ecosystem to reach 2035, aiming to resolve systemic tensions between biomedical innovation and workforce deficits through widespread AI automation and GLP-1 cost management. The panel identifies critical risks such as proposed 40% cuts to NIH funding, FDA staffing reductions, and regulatory bottlenecks that threaten to undermine US leadership in global life sciences despite breakthroughs like xenotransplantation. Concluding that hope is not a strategy, the consensus calls for immediate cross-sector collaboration to align incentives, secure foundational research funding, and modernize infrastructure to prevent China from seizing global health dominance.
- Milken Institute1h 1m
Where Is the Next Cure? | Global Conference 2024
Alice Park, Noubar Afeyan, Aloe Blacc, Daphne Koller, Samarth Kulkarni, Pablo Legorreta
Leading biotech executives and researchers are redefining the industry by shifting from chronic small-molecule management to precise, curative systems-based therapies like CRISPR and mRNA platforms. This transition, fueled by artificial intelligence and a "reverse translation" innovation model, has accelerated clinical timelines while projecting a $100 billion market for GLP-1 drugs and new organ-editing solutions. Despite regulatory hurdles and high initial costs for treatments like sickle cell gene editing, stakeholders anticipate that maturing technologies and scalable manufacturing will eventually democratize access to these transformative medical breakthroughs.
- Milken Institute43 min
Partnerships Leading to a Healthier Tomorrow | Future of Health Summit 2024
Meg Tirrell, Yele Aluko, John Crowley, Kody Kinsley, Pablo Legorreta
Moderated by a panel including BIO President John Crowley and North Carolina HHS Secretary Cody Kinsley, industry leaders and officials discussed strategies to overcome systemic inefficiencies and reduce the $500 billion in annual waste within the US healthcare sector. Speakers highlighted North Carolina's successful Medicaid expansion and debt relief initiatives as a model for addressing social determinants of health, while advocating for regulatory reforms and non-dilutive financing to accelerate biotechnology innovation. The dialogue concluded with a unified call to shift the industry focus from reactive volume-based care to preventive measures and equitable access, emphasizing the role of technology in creating a more sustainable and efficient national health system.
- Milken Institute1h 0m
Transformative Philanthropy and Innovation | Milken Institute Global Conference 2024
Melissa Stevens, Pablo Legorreta, Strive Masiyiwa, Louise Richardson, Mark Walter
CEO Mark Walter, Strive Masiwa, Dame Louise Richardson, and Pablo Legareta convened to define transformative philanthropy as high-risk capital that drives systemic change in healthcare, education, and conservation. The panel detailed specific strategies such as Legareta's medical therapies for transplant patients, Walter's vocational schools in Chicago, and community-integrated conservation models in Zimbabwe that successfully reduced rhino poaching. Ultimately, the leaders agreed that effective philanthropy must prioritize sustainable governance and local resource mobilization to mitigate polarization and create a self-sustaining future.
- Milken Institute56 min
Preserving the Promise of Cancer Immunotherapy
Louise Perkins, Pablo Legorreta, Johanna Mercier, Jill O'Donnell-Tormey, Antoni Ribas, Greg Simon
The Melanoma Research Alliance, alongside the Biden Cancer Initiative and L'Oréal Paris, is addressing the persistent 50% non-response rate to current immunotherapies by promoting platform trials and data-sharing networks to eliminate redundant "Me Too" drug development. While recent clinical advances have extended survival for metastatic patients to a decade or more, experts emphasize the urgent need to de-risk academic discoveries through nonprofit incubators and standardized liquid biopsies to prevent early-stage cancer from progressing to terminal stages. Strategic recommendations from industry leaders and researchers prioritize patient-centric trial design and sustained basic science funding to ensure these breakthroughs reach community oncologists and avoid investment withdrawal from other critical therapeutic classes.